Cancer incidence among pesticide applicators exposed to trifluralin in the Agricultural Health Study
Cancer incidence among pesticide applicators exposed to trifluralin in the Agricultural Health Study
复制标题
DOI：
10.1016/j.envres.2008.01.010
复制
发表时间：
2008-06-01
影响因子：
8.3
通讯作者：
Alavanja, Michael
中科院分区：
文献类型：
--
作者：
Kang, Daehee;Park, Sue Kyung;Alavanja, Michael
氟乐灵，即2,6 - 二硝基 - N,N - 二丙基 - 4 - 三氟甲基苯胺，是一种2,6 - 二硝基类除草剂，广泛用于农业环境中防治一年生禾本科杂草和阔叶杂草。在农业健康研究（AHS）中，对爱荷华州和北卡罗来纳州的50127名私人和商业农药施用者评估了氟乐灵使用与常见癌症发病率之间的关联，该研究是一项对持证农药施用者及其配偶进行的前瞻性队列研究。在控制重要的生活方式因素和其他农业接触因素的同时，使用泊松回归检验内部剂量 - 反应关系。在与未接触的施用者以及接触量处于最低三分位数的施用者作为参照组进行的接触 - 反应分析中，使用了两种接触指标（终生接触天数和强度加权终生接触天数）。从1993年登记到2002年期间，通过州肿瘤登记处确定了癌症发病情况。在使用过氟乐灵的51%的私人和商业施用者（n = 25712）中，氟乐灵接触总体上与癌症发病率无关。然而，在最高三分位数的较高一半接触类别中，结肠癌发病率过高（以未接触者为参照，比率比（RR）为1.76（95%置信区间 = 1.05 - 2.95）；以接触量处于最低三分位数者为参照，比率比为1.93（95%置信区间 = 1.08 - 3.45））。在最高接触组中，肾癌和膀胱癌的风险也有非显著升高，尽管只有肾癌的结果在不同接触指标中是一致的。尽管氟乐灵接触与结肠癌之间可能存在联系，但剂量 - 反应和亚组分析中的数量少以及不一致情况表明，这可能是一个偶然发现。由爱思唯尔公司出版。
Trifluralin, 2,6-dinitro-N,N-dipropyl-4-trifluoromethylaniline, is a 2,6-dinitro herbicide widely used to control annual grasses and broadleaf weeds in agricultural settings. The association between trifluralin use and common cancer incidence was evaluated among 50,127 private and commercial pesticide applicators in the Agricultural Health Study (AHS), a prospective cohort study of licensed pesticide applicators and their spouses in Iowa and North Carolina. Poisson regression was used to examine internal dose-response relationships, while controlling for important lifestyle factors and other agricultural exposures. Two metrics of exposure (lifetime days and intensity-weighted lifetime days) were used in exposure-response analyses with non-exposed applicators, as well as applicators in the lowest tertile of exposure, as reference groups. Incident cancers were identified through state tumor registries from enrollment in 1993 through 2002. Trifluralin exposure was not associated with cancer incidence overall among 51% of private and commercial applicators (n = 25,712) who had used trifluralin. However, there was an excess of colon cancer in the exposure category of higher half of highest tertile (rate ratios (RR) of 1.76 (95% CI = 1.05-2.95) using the non-exposed as a referent and 1.93 (95% CI = 1.08-3.45) using those with the lowest tertile of exposure as the referent). There was also a non-significantly elevated risk for kidney cancer and bladder cancer in the highest exposure group, although only the kidney cancer finding was consistent across exposure metrics. Although there was a possible link between trifluralin exposure and colon cancer, small numbers and inconsistencies in dose-response and subgroup analyses indicate that this may be a chance finding. Published by Elsevier Inc.